Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Income (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Net Income for 13 consecutive years, with -$58.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 1.63% to -$58.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$285.0 million, a 38.82% increase, with the full-year FY2025 number at -$285.0 million, up 38.82% from a year prior.
  • Net Income was -$58.4 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$111.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$42.2 million in Q2 2025 to a low of -$152.0 million in Q2 2024.
  • A 5-year average of -$83.1 million and a median of -$75.1 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 91.87% in 2024, then soared 72.21% in 2025.
  • Madrigal Pharmaceuticals' Net Income stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then crashed by 30.6% to -$112.2 million in 2023, then soared by 47.04% to -$59.4 million in 2024, then increased by 1.63% to -$58.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Net Income are -$58.4 million (Q4 2025), -$111.1 million (Q3 2025), and -$42.2 million (Q2 2025).